Reported Earnings • May 18
First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.32 loss in 1Q 2025) First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.32 loss in 1Q 2025). Revenue: US$1.11m (down 24% from 1Q 2025). Net loss: US$3.22m (loss widened 159% from 1Q 2025). Aankondiging • Apr 12
Callan JMB Inc. Receives Nasdaq Notice of Non-Compliance with Stockholders' Equity Requirement On April 7, 2026 Callan JMB Inc. (the Company) received a deficiency letter (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market (the Stockholders' Equity Requirement). In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 22, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement. Subsequent to the receipt of the Notice, and prior to that deadline, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement to Nasdaq. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq may, in its discretion, grant the Company up to 180 calendar days from the date of the Notice, or until October 4, 2026, to evidence compliance. Neither the Notice nor the Company's non-compliance have an immediate effect on the listing or trading of the Company's common stock, which will continue to trade under the symbol CJMB. However, these can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance. New Risk • Apr 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (82% average weekly change). Revenue has declined by 13% over the past year. Market cap is less than US$10m (US$7.37m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). Reported Earnings • Apr 04
Full year 2025 earnings released: US$1.82 loss per share (vs US$0.87 loss in FY 2024) Full year 2025 results: US$1.82 loss per share (further deteriorated from US$0.87 loss in FY 2024). Revenue: US$5.72m (down 13% from FY 2024). Net loss: US$7.97m (loss widened 247% from FY 2024). Aankondiging • Mar 11
Callan Jmb Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’S Ind Clinical Trials for Lodonal™ in the Treatment of Long Covid Callan JMB Inc. announced that it has agreed with Biostax Corp. d/b/a Attune Biotech Inc. to support its investigational new drug clinical trials for the treatment of Post-Acute Sequelae of SARS-CoV-2 infection (“PASC”), commonly known as Long COVID. The Company previously announced in January 2026, that it had signed a strategic teaming agreement with Attune, whereby Callan JMB serves as independent third-party overseer of Attune's manufacturing, quality assurance and control, and deployment operations. Under this agreement, Callan JMB will provide the following services and oversight for IND 181314 for JKB-122 (lodonal™), including Contract Manufacturing Organization (CMO) qualification and validation, comprehensive batch record review, supply chain verification and integrity confirmation, surge manufacturing capacity assessment, and distribution pathway validation. Attune has received notification that the U.S. Food and Drug Administration (FDA) has received and assigned Investigational New Drug (IND) application number 181314 for JKB-122 (lodonal™) for treatment of Long COVID, which remains a condition for which no FDA-approved therapies are currently indicated. Patients of Long COVID are currently underserved, with approximately 20 million Americans estimated to be living with Long COVID or persistent post-COVID symptoms. In addition, the U.S. Department of Health and Human Services (HHS) has issued formal guidance titled “Long COVID as a Disability Under the ADA, Section 504, and Section 1557” (last reviewed July 2025), confirming that Long COVID may qualify as a disability under federal civil rights statutes where symptoms substantially limit major life activities. lodonal™ (JKB-122) is a first-in-class TLR4 antagonist for immune restoration, currently in development across five parallel clinical programs including Long COVID, HIV immune non-responders, autoimmune hepatitis, metabolic liver diseases (MASLD/MASH), and chronic immune pain. Under IND 181314, Attune intends to initiate a randomized, double-blind, placebo-controlled, multi-center Phase 2b/3 clinical trial evaluating the safety, tolerability, and efficacy of JKB-122 (lodonal™) in adults diagnosed with PASC or Long COVID. The product remains investigational and has not been approved by the U.S. Food and Drug Administration. JKB-122 is protected by issued intellectual property extending through 2041. New Risk • Jan 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 81% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (81% average weekly change). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$5.18m market cap). Aankondiging • Dec 07
Callan JMB Inc. Appoints Christopher Shields as Interim Chief Financial Officer, Effective December 1, 2025 Callan JMB Inc. appointed Christopher Shields, the Company’s Senior Vice President (Governmental Affairs), to serve as Interim Chief Financial Officer until a permanent Chief Financial Officer is appointed, effective December 1, 2025. Mr. Shields, age 57, has served as the Company’s Senior Vice President (Governmental Affairs), since April 15, 2025, pursuant to the employment agreement, dated March 15, 2025. Prior to joining the Company, Mr. Shields served as Assistant Commissioner (Bureau of Preparedness and Response) with Chicago Department of Public Health, City of Chicago, from February 2011 to March 2025, where he led City of Chicago’s efforts to prepare for and respond to the health consequences of disasters including severe weather, special events, infectious diseases, chemical/biological/radiological releases. Additionally, Mr. Shields has more than three decades of experience managing operations and logistics components of various stages and branches of public health emergency preparedness and response, among others. Mr. Shields received a B.S., in Community Health Administration in 1990 from Northern Illinois University, DeKalb, Illinois, and also completed the Critical Infrastructure Protection Certificate Program at the Texas A&M Engineering Extension Service (TEEX) between 2016 to 2017. Mr. Shields currently serves on Northern Illinois University’s College of Health and Human Sciences Advisory Board. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). New Risk • Dec 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap). Aankondiging • Dec 01
Callan JMB Inc., Annual General Meeting, Dec 29, 2025 Callan JMB Inc., Annual General Meeting, Dec 29, 2025. Reported Earnings • Nov 17
Third quarter 2025 earnings released: US$0.61 loss per share (vs US$0.27 loss in 3Q 2024) Third quarter 2025 results: US$0.61 loss per share (further deteriorated from US$0.27 loss in 3Q 2024). Revenue: US$1.45m (flat on 3Q 2024). Net loss: US$2.73m (loss widened 239% from 3Q 2024). Aankondiging • Nov 11
Callan JMB Inc. Expands Logistics Platform into Food Sampling Sector, Advancing Multi-Variant Growth Strategy Callan JMB Inc. announced the expansion of its reclamation operations into the food sampling industry. This move is part of Callan JMB's multi-variant strategic growth initiative designed to extend its proven compliance-driven model into adjacent, high-growth markets. Building on a long history of excellence in pharmaceutical and regulated material logistics, Callan JMB is applying its expertise in product integrity, recall readiness, and traceability to support the specialized needs of food brands and distributors managing large-scale sampling programs. While most food sampling programs focus on reach and trial, few have standardized sustainable packaging or waste-reduction practices -- creating an accountability gap. As brands face increasing pressure to cut waste and measure impact, the sampling channel presents a clear opportunity for logistics partners that deliver sustainability, compliance, and traceability. The expansion was made possible through Callan JMB's relationship with Keychain, an AI-powered platform for the consumer packaged goods (CPG) industry. Supporting over $1 billion in monthly manufacturing projects, Keychain's platform connects 30,000 manufacturers with 20,000 brands and retailers, helping them bring new products to market faster, more responsibly, and with greater precision. While specific forecasts for food sampling services are limited, the broader food logistics market--valued at over $120 billion globally and growing at a rate of 6-10% annually-- offers a strong platform for expansion. Callan JMB's entry into this fast-emerging segment supports brands responding to the growing demand for sustainable, compliant sampling and distribution. With the U.S. specialty food sector projected to reach $130 billion by 2032 (Data Bridge Market Research, 2024), this expansion reinforces Callan JMB's commitment to diversification, sustainability, and cross-sector resilience. Aankondiging • Oct 14
Callan Jmb Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring Callan JMB INC. announced that it has upgraded its proprietary Sentry Monitoring System technology with version 4.0 for temperature-sensitive storage to significantly increase flexibility and accessibility for its customers. The Sentry Monitoring System is a platform that allows remote monitoring of refrigerators, freezers, and clean room temperatures for high-value pharmaceutical products in pharmacies, hospitals, and emergency preparedness facilities. The upgraded version, Sentry 4.0, provides the user with the same 24/7/365 active monitoring by Callan JMB staff, alarm notifications, and compliant reporting data that are currently available with the Sentry 3 system, but with improved accessibility for users on the go. Sentry 4.0 allows users to access a consistent interface across all systems and devices - PC or Mac, an iPhone or Android, or any tablet. This flexibility enables the customer to address environmental anomalies in their pharmaceutical storage units from any available device, without having to download additional programs. With Sentry 4.0, Callan JMB has raised the bar for secure, reliable, and easy-to-use temperature monitoring that is critical to the medical and pharmaceutical industries. The upgraded system is now available to new and existing customers. Reported Earnings • Aug 15
Second quarter 2025 earnings released: US$0.31 loss per share (vs US$0.015 loss in 2Q 2024) Second quarter 2025 results: US$0.31 loss per share (further deteriorated from US$0.015 loss in 2Q 2024). Revenue: US$1.67m (down 16% from 2Q 2024). Net loss: US$1.40m (loss widened US$1.28m from 2Q 2024). Aankondiging • Jul 26
Callan JMB Inc. announced that it expects to receive $25 million in funding Callan JMB Inc. announced it has entered into a Purchase Agreement with a certain investor (ELOC agreement) whereby the Company has the right, but not the obligation, to sell to the Investor, up to an aggregate of $25,000,000 of shares (the “ ELOC Shares ”) of the Company’s common stock, par value $0.001 per share, subject to the terms and conditions on July 24, 2025. The term of the Purchase Agreement is through the first day of the month immediately following the eighteen (18) month anniversary of the Commencement Date or the date on which the Investor has purchased ELOC Shares pursuant to the Purchase Agreement for an aggregate purchase price of the Investment Amount. The Company has also agreed to issue to the Investor 15,000 shares of Common Stock (the “ Commitment Shares ”), to be issued to the Investor upon the effectiveness of the registration statement registering the resale of the ELOC Shares and the Commitment Shares. The issuance of the shares of ELOC Shares to the Investor is being made pursuant to exemptions from the registration requirement of the Securities Act of 1933, as amended (the “ Securities Act ”) provided by Section 4(a)(2) of the Securities Act. Reported Earnings • May 16
First quarter 2025 earnings released: US$0.32 loss per share (vs US$0.032 loss in 1Q 2024) First quarter 2025 results: US$0.32 loss per share (further deteriorated from US$0.032 loss in 1Q 2024). Revenue: US$1.45m (down 19% from 1Q 2024). Net loss: US$1.24m (loss widened US$1.16m from 1Q 2024). Aankondiging • Apr 25
Callan JMB Inc. Appoints Christopher Shields, as Senior Vice President of Emergency Preparedness & Response/Government Affairs Callan JMB INC. announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Mr. Shields is an industry veteran with decades of experience managing complex public safety responses to a diverse array of crises both domestically and internationally. Most recently, Mr. Shields served for over 14 years as Assistant Commissioner at the Chicago Department of Public Health, where he oversaw operations and logistics for the city’s Emergency Preparedness and Bioterrorism program. His responsibilities included managing day-to-day operations of the Tier 1 Medical Pharmacy, overseeing advanced vaccine inventory and storage systems, and leading critical functions such as the Continuity of Operations group, Emergency Operations Planning team, and Tactical Communications platform. Mr. Shields has held various leadership positions responsible for humanitarian aid/disaster relief (HADR) and emergency responses to health impacts including September 11, 2001, Hurricane Katrina 2005, H1N1 Pandemic 2009-2010, NATO 2012, Ebola 2014-2016, Hurricane Maria, SARSCoV-2 Pandemic 2020-2023, Operation Allies welcome, Monkey Pox MPV outbreak 2022, humanitarian migration response from South America (2022 - ongoing), Ebola (Sudan virus) 2022-2023, Measles 2024, the Democratic National Convention (DNC) 2024 and the Rwanda Marburg operation/ORD 2024. Recent Insider Transactions • Apr 04
Chief Medical Officer recently bought US$113k worth of stock On the 27th of March, David Croyle bought around 25k shares on-market at roughly US$4.50 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$253k. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months. Board Change • Mar 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive VP & Director Eric Kash is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Mar 30
Full year 2024 earnings released: US$0.87 loss per share (vs US$0.44 profit in FY 2023) Full year 2024 results: US$0.87 loss per share (down from US$0.44 profit in FY 2023). Revenue: US$6.56m (down 50% from FY 2023). Net loss: US$2.29m (down 205% from profit in FY 2023). Aankondiging • Feb 28
Callan Jmb Inc. Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations Callan JMB INC. announced a new comprehensive lease program for vaccine management that will enable government agencies and private organizations to provide crucial immunizations without the economic burden of purchasing the necessary equipment outright. Under this program, Callan JMB can not only assist agencies in developing their plans, but can lease refrigerators, freezers, ultra-cold units, and generators to them, all monitored by Callan JMB's proprietary Sentry monitoring system. The lease program includes computer equipment, compliant inventory management, and mobile clinic kits that keep vaccines at required temperatures throughout transit and include everything needed for successful immunizations. While there are grants available for vaccine management plans through Public Health Emergency Preparedness (PHEP) programs, many do not cover the purchase of equipment. Drawing on extensive emergency preparedness and response logistics expertise, Callan JMB's vaccine and compliance specialists offer this lease program across all public health initiatives--from immunization programs and rural medical response units to pandemic preparedness plans. The program delivers a state-of-the-art, full-service management system emphasizing quality, responsibility, and accountability. Since 2009, Callan JMB has pioneered the development of fully compliant vaccine management centers for secure storage and efficient distribution. The COVID-19 pandemic proved to be the ultimate test for these facilities, with the Company's centers in Texas, Oregon, and Illinois demonstrating exceptional effectiveness. From April 2020 through January 2024, Callan JMB successfully managed the distribution of 2.27 million COVID-19 vaccine doses, 32.2 million testing supplies, and 113,401 COVID-19 therapeutics for the Texas Department of State Health Services. Aankondiging • Feb 10
Callan JMB Inc. Appoints Three Directors to Its Board of Directors On February 4, 2025, Callan JMB Inc. appointed three directors (the New Directors") to its board of directors (the Board of Directors"). The New Directors are Liberty Duke, Mark Meller and Gerald Dial. Each of the New Directors has been appointed a member of the Company's Audit, Compensation and Nominating and Corporate Governance committees. Mr. Meller has been appointed Chair of the Audit Committee, Ms. Duke has been appointed Chair of the Compensation Committee and Mr. Dial has been appointed Chair of the Nominating and Corporate Governance Committee.